Novo Nordisk A/S is trading 2.2% up today at $292.45 after the company announced plans to seek regulatory approval for an oral version of its Wegovy weight-loss drug in China.
- The move is strategically aimed at expanding the company's obesity franchise and establishing a stronger market position to counter future generic competition.
- Investor sentiment is also being modestly supported by a generally positive tone across the broader equity markets.